{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:17:50Z","timestamp":1792279070057,"version":"4.4.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00740","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T01:09:41Z","timestamp":1589850581000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Troponins and Natriuretic Peptides in Cardio-Oncology Patients\u2014Data From the ECoR Registry"],"prefix":"10.3389","volume":"11","author":[{"given":"Lena","family":"Hinrichs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone Maria","family":"Mrotzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca-Ileana","family":"Mincu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"R\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Abbas","family":"Mahabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Al-Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Totzeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/pbc.21100","article-title":"B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children","volume":"49","author":"Aggarwal","year":"2007","journal-title":"Pediatr. Blood Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/1097-0142(19920315)69:6<1492::AID-CNCR2820690630>3.0.CO;2-3","article-title":"Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects","volume":"69","author":"Bauch","year":"1992","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","article-title":"Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy","volume":"36","author":"Cardinale","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s11936-008-0041-x","article-title":"Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy","volume":"10","author":"Cardinale","year":"2008","journal-title":"Curr. Treat Options Cardiovasc. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.seminoncol.2013.01.008","article-title":"Strategies to prevent and treat cardiovascular risk in cancer patients","volume":"40","author":"Cardinale","year":"2013","journal-title":"Semin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/14737159.2017.1283219","article-title":"Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy","volume":"17","author":"Cardinale","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"B10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1053\/j.seminoncol.2019.11.002","article-title":"Cardio-oncological management of patients","volume":"46","author":"Cardinale","year":"2019","journal-title":"Semin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1","volume":"70","author":"Chang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2","volume":"70","author":"Chang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1034","DOI":"10.1634\/theoncologist.2018-0773","article-title":"Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer","volume":"24","author":"Curigliano","year":"2019","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","article-title":"Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging","volume":"18","author":"Galderisi","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1161\/01.CIR.95.8.2053","article-title":"Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina","volume":"95","author":"Galvani","year":"1997","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijcard.2005.05.006","article-title":"Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines","volume":"108","author":"Germanakis","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrcardio.2013.129","article-title":"Cardiac troponin level elevations not related to acute coronary syndromes","volume":"10","author":"Giannitsis","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/1078155214567162","article-title":"Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study","volume":"22","author":"Gunaldi","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.ahj.2009.07.021","article-title":"Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: data from the Heart and Soul study","volume":"158","author":"Hsieh","year":"2009","journal-title":"Am. Heart J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.jacc.2007.06.037","article-title":"Early Breast Cancer Therapy and Cardiovascular Injury","volume":"50","author":"Jones","year":"2007","journal-title":"J.  Am. Coll. Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/0022-2828(89)90680-9","article-title":"Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients","volume":"21","author":"Katus","year":"1989","journal-title":"J. Mol. Cell Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry","volume":"41","author":"Lopez-Sendon","year":"2020","journal-title":"Eur. Heart J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J.  Am. Coll. Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1067\/mhj.2001.113215","article-title":"Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction","volume":"141","author":"Maisel","year":"2001","journal-title":"Am. Heart J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1081\/CNV-100103130","article-title":"Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study","volume":"19","author":"Mathew","year":"2001","journal-title":"Cancer Invest."},{"key":"B28","doi-asserted-by":"publisher","first-page":"S4282","DOI":"10.21037\/jtd.2018.08.15","article-title":"Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity","volume":"10","author":"Michel","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2019.100420","article-title":"Cardiotoxicity from immune checkpoint inhibitors","volume":"25","author":"Michel","year":"2019","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography","volume":"32","author":"Mitchell","year":"2019","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"B31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1046\/j.1365-2796.2002.00951.x","article-title":"Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction","volume":"251","author":"Nousiainen","year":"2002","journal-title":"J. Intern. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","article-title":"Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality","volume":"101","author":"Pavo","year":"2015","journal-title":"Heart"},{"key":"B33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail"},{"key":"B34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11739-011-0744-y","article-title":"Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology","volume":"7","author":"Raschi","year":"2012","journal-title":"Intern. Emerg. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"S4386","DOI":"10.21037\/jtd.2018.11.110","article-title":"Modern concepts in cardio-oncology","volume":"10","author":"Rassaf","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/j.jacc.2017.08.064","article-title":"Stable High-Sensitivity Cardiac Troponin T Levels and Outcomes in Patients With Chest Pain","volume":"70","author":"Roos","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/eurheartj\/ehu188","article-title":"Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction","volume":"35","author":"Rubini Gimenez","year":"2014","journal-title":"Eur. Heart J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1373\/clinchem.2005.050153","article-title":"N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction","volume":"51","author":"Sandri","year":"2005","journal-title":"Clin. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/ehjci\/jex033","article-title":"2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility","volume":"18","author":"Santoro","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"B42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00280-017-3420-8","article-title":"Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value","volume":"80","author":"Skubitz","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B43","first-page":"1197","article-title":"Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy","volume":"26","author":"Soker","year":"2005","journal-title":"Saudi Med. J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.lab.2005.02.003","article-title":"Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines","volume":"145","author":"Specchia","year":"2005","journal-title":"J. Lab. Clin. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/hj.1998.v136.89908","article-title":"Elevated B-type natriuretic peptide levels after anthracycline administration","volume":"136","author":"Suzuki","year":"1998","journal-title":"Am. Heart J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11936-018-0641-z","article-title":"Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment","volume":"20","author":"Tan","year":"2018","journal-title":"Curr. Treat Options Cardiovasc. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth universal definition of myocardial infarction, (2018)","volume":"40","author":"Thygesen","year":"2018","journal-title":"Eur. Heart J."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"B49","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/2047487318755193","article-title":"Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients","volume":"25","author":"Totzeck","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ehf2.12493","article-title":"Heart failure from cancer therapy: can we prevent it","volume":"6","author":"Totzeck","year":"2019","journal-title":"ESC Heart Fail"},{"key":"B51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijcard.2019.01.038","article-title":"Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease","volume":"280","author":"Totzeck","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.2174\/092986712800492977","article-title":"Biomarkers as a guide of medical treatment in cardiovascular diseases","volume":"19","author":"Vavuranakis","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ijcard.2007.02.003","article-title":"BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxity","volume":"124","author":"Vogelsang","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.3892\/ol.2016.4424","article-title":"Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity","volume":"11","author":"Wang","year":"2016","journal-title":"Oncol. Lett."},{"key":"B55","first-page":"99","article-title":"B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide - Diagnostic role in stable coronary artery disease","volume":"11","author":"Weber","year":"2006","journal-title":"Exp. Clin. Cardiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehw359","article-title":"An ESC position paper on cardio-oncology","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T01:09:44Z","timestamp":1589850584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":57,"alternative-id":["10.3389\/fphar.2020.00740"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00740","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"article-number":"740"}}